PubMed Health⌕ Search

Biomedical subjects

A Yaffe

Publications and source records attributed to A Yaffe.

At least 19 recordsLinked to original sources
PubMed2006

Effect of low intensity laser irradiation on surgically created bony defects in rats.

Low intensity lasers have been used by clinicians to improve healing and reduce pain in humans. Lasing also results in new bone formation around hydroxyapatite implants and a significant increase in the total bone area. However, the exact mechanism of cell biostimulation by laser is still unclear. This study biochemically assessed the effects of low intensity laser (Gallium-Arsenide) using 4 and 22.4 mW cm(-2) power density on the bone healing process after surgically creating bony cavities in rat mandibles. Rats (n = 24) were divided into two groups each treated with specific energy, 4 or 22.4 mW cm(-2), for 3 min each day post-surgery. Surgical cavities were created on both sides of the mandible: the left served as an untreated control, the right was treated with laser. All rats were sacrificed after 1, 2 and 4 weeks of treatment. In the newly formed callus, accumulation of radiocalcium and alkaline phosphatase activity was measured to indicate osteogenic activity. One-way anova with repeated measures showed that the low intensity laser using 4 mW cm(-2) power density significantly increased radiocalcium accumulation from 2 weeks post-surgery, whereas 22.4 mW cm(-2) had no effect. No changes were noted in the activity of alkaline phosphatase with the laser treatment. These results suggest that laser therapy of low power density is effective on the bone healing process in artificially created osseous cavities by affecting calcium transport during new bone formation.

Alkaline Phosphatase↗
PubMed2005

Use of complementary and alternative medicine among cancer patients in Israel.

Complementary and alternative medicine (CAM) has gained in popularity among cancer patients in recent years. The present study assessed the patterns of CAM use among cancer patients in Israel. The design of the study was descriptive cross-sectional, and data were collected using a 27-item questionnaire. The sample consisted of 111 Israeli cancer patients who were part of a larger European study. Among the participants, past or current CAM use was reported by 32.4% (n=36). The most common therapies used included herbal medicine (22.2%), spiritual therapies (19.4%), visualization and relaxation techniques (16.7% for each), and vitamins/minerals (13.9%). Younger patients with higher education, higher annual income, and previous standard treatment were more likely to use CAM. The mean satisfaction and perceived effectiveness scores were 5.36+/-1.37 and 5.48+/-1.39, respectively, out of a maximum score of 7. The main benefits from CAM reported by patients included improvement in emotional and physical well-being (40% and 34.3%, respectively) and increased ability to fight the disease (31.4%), although 17.1% of patients reported no benefits at all from CAM. The main sources of information about CAM were friends/family and the media. Findings suggest that due to the relatively high use of CAM among cancer patients, this topic should be taken into account in a holistic approach to this patient population.

Adult↗
PubMed2005

Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients.

AIMS: To compare the efficacy of insulin pump treatment with multiple daily injections in the treatment of poorly controlled obese Type 2 diabetic patients already receiving two or more daily injections of insulin plus metformin. METHODS: Forty obese Type 2 diabetic subjects (using insulin) were randomized to treatment with continuous subcutaneous infusion pump (CSII) (Minimed) or multiple daily insulin injections (MDI). At the end of the first 18-week treatment period, patients underwent a 12-week washout period during which they were treated with MDI plus metformin. They were then crossed-over to the other treatment for an 18-week follow-up period. Patients performed 4-point daily self blood-glucose monitoring (SBGM) on a regular basis and 7-point monitoring prior to visits 2, 8, 10 and 16. A subset of patients underwent continuous glucose monitoring using the Minimed(R) continuous glucose monitoring system (CGMS) at visits 2, 8, 10 and 16. A standard meal test was performed in which serum glucose was tested at fasting and once each hour for 6 h following a test meal. Glucose levels were plotted against time and the area under the curve (AUC) was calculated. HbA(1c), weight, daily insulin dose and hypoglycaemic episodes were recorded. RESULTS: In obese Type 2 diabetic patients already treated with insulin, treatment with CSII significantly reduced HbA(1c) levels compared with treatment with MDI. An additional CSII treatment benefit was demonstrated by reduced meal-test glucose AUC. Initial reduction of daily insulin requirement observed in CSII-treated subjects during the first treatment period was attributable to a period effect and did not persist over time. CONCLUSIONS: In the intent-to-treat analysis, CSII appeared to be superior to MDI in reducing HbA(1c) and glucose AUC values without significant change in weight or insulin dose in obese, uncontrolled, insulin-treated Type 2 diabetic subjects.

Adult↗
PubMed2003

Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats.

BACKGROUND: Recent animal studies have shown that a combination of chemically-modified tetracyclines together with bisphosphonates, when delivered systemically, are synergistically effective in suppressing periodontal bone loss. In the present study, we explored the combined efficacy of local delivery of alendronate and tetracyclines in reducing alveolar bone loss. METHODS: Eighty-six (86) male Wistar rats were used in these experiments. The flap was elevated using a special periosteal elevator, on both sides of the mandible, as described previously. A gelfoam pellet containing the drugs was applied between the alveolar bone and the mucoperiosteal flap, according to the experimental protocol. The rats were divided into 5 treatment groups: 1) alendronate; 2) doxycycline hyclate 10% (DOXY); 3) tetracycline hydrochloride 1% (TET); 4) alendronate + DOXY; and 5) alendronate + TET. In the operated control sites (C), saline was applied. The rats were sacrificed 21 days following the flap procedure. Sections of the mandibles (1.5 mm), in a buccal-lingual direction, underwent microradiography and were analyzed for bone loss. RESULTS: DOXY alone was most effective in reducing bone loss. Alendronate was also effective in reducing bone loss as shown in previous reports. TET did not reduce bone loss significantly when used alone. In combination with alendronate TET was synergistically effective. The combined local treatment of alendronate + DOXY showed no additive effect. CONCLUSIONS: In the present study, we found that tetracyclines can be most effective in reducing alveolar bone loss when applied locally. The combined local treatment of alendronate and tetracycline may have a synergistic effect.

Administration, Topical↗
PubMed2001

Alveolar bone resorption following coronal versus apical approach in a mucoperiosteal flap surgery procedure in the rat mandible.

BACKGROUND: In several publications, we have reported that a distinct resorptive phase of alveolar bone developed during 3 weeks following elevation of a mucoperiosteal flap in rats by a coronal surgical approach. In the present study, we compared the alveolar bone loss after mucoperiosteal flap surgery by a coronal approach (COR) to a surgical approach incising the mucosa close to the tooth apices and separating the mucoperiosteum toward the tooth crown (apical approach, AP). METHODS: Eighteen Wistar rats were divided into 2 experimental groups; each group consisted of 9 rats. In the first group, COR was performed on both buccal and lingual aspects on the right side of the rat mandible, while the left side served as a sham-operated control. In the second experimental group, AP was performed. RESULTS: In the AP group, the outer aspect (buccal or lingual) of the alveolar bone was slightly resorbed usually at the level where the mucosa was incised. In many sections, extensive modeling of new trabecular bone was seen, coronal to the surgical incision. On the contrary, the coronal surgical approach revealed an extensive resorptive phase, mainly of the periodontal aspect of the alveolar bone. CONCLUSIONS: The results of this study show that periodontal surgery by a coronal surgical approach stimulates a burst of remodeling of the alveolar bone in a very specific pattern.

Alveolar Bone Loss↗
PubMed2001

[Splinting--a review of the literature].

Early evidence for the use of splints can be seen in ancient civilizations, but the concept of Splinting teeth to support and immobilize teeth, by joining several teeth together continues to be a topic of controversy. Splints can be classified based on their purpose and duration of use, the way of fabrication, and the location of the splinted teeth in the jaw. The biomechanical mechanism of splint is related to the mechanism of tooth mobility. The indications for splint usage in the healthy and diseased periodontium are variable, among them are: prevention of mobility after acute trauma, for occlusal therapy, to allow function, to allow periodontal repair, in case of occlusal trauma, to prevent teeth drifting after orthodontic treatment or when a tooth is missing. Due to the many disadvantages splints have, splinting should be used cautiously, specially in splinting teeth and implants.

Dental Occlusion, Traumatic↗
PubMed2000

The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.

BACKGROUND: Periodontal surgery stimulates osteoclast activity, leading to varying amounts of alveolar crest loss. We have established that topical application of 20 mg/ml of alendronate placed at the surgical mucoperiosteal site produced a striking reduction of alveolar bone loss in the rat model. The aim of this investigation was to examine the antiresorptive efficacy of 3 novel bisacylphosphonates topically delivered at the surgical site, in comparison to alendronate and etidronate which are in clinical use. METHODS: Mucoperiosteal flap (MF) surgery was performed on the buccal and lingual aspects next to molars on both sides of the rat mandible. A gelatin sponge soaked in the bisphosphonate solution prepared by dissolving 20 mg of the bisphosphonate (alendronate, etidronate, VS-5, VS-6, ISA-13, SuBP) in 1 ml of saline was applied to exposed bone on the right side of the mandible (experimental, MF + BPs ) and the left side was treated with saline only (control, MF + S). Sections were evaluated for bone loss using microradiography pattern and amount. RESULTS: The 3 novel bisacylphosphonates, VS-5 VS-6, and ISA-13 were more effective than etidronate, and less effective than alendronate. The most effective among this group was ISA-13 followed by VS-5 and VS-6. CONCLUSION: We conclude that ISA-13-like alendronate is effective in reducing alveolar bone loss when delivered at surgical sites. Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue.

Administration, Topical↗
PubMed2000

Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats.

BACKGROUND: Mucoperiosteal flaps are used to access bone and root surfaces for debridement, pocket elimination, management of periodontal defects, and in regenerative procedures, as well as in implant surgery. Many reports show that periodontal surgery stimulates osteoclast activity with varying amounts of alveolar bone loss. Alendronate given intravenously significantly reduced alveolar bone loss in mucoperiosteal flap procedures. In the present study, we explored the effectiveness of different concentrations of alendronate, delivered at the surgical site at the time of surgery, in distant delivery in reducing alveolar bone loss. METHODS: Following elevation of a mucoperiosteal flap next to molars of the rat mandible, a gelatin sponge soaked with different concentrations of alendronate (0, 1, 5, 20, or 40 mg/ml; experiment A) was applied to exposed bone on the experimental side. In the second group (experiment B), alendronate (0, 50, 200, or 400 microg) was topically delivered in the cheek submucosa on the left side (distant to the surgical site) in a small cut into which the gelatin sponge soaked with the drug was placed. RESULTS: Topical application of 200 microg and 400 microg doses of alendronate at the time of surgery was significantly effective (P <0.001) in reducing bone loss. Generally, the percentage of sections with mild bone loss (V1, V2) increased with an increase in the dose of alendronate, while the percentage of sections with severe bone loss (H1, H2) decreased with an increase in alendronate dose. Topical application of 400 microg of alendronate had a systemic effect. CONCLUSIONS: This study implies that topical delivery of alendronate at the time of surgery reduces bone loss in periodontal procedures involving mucoperiosteal flap surgery. The most effective dose is 200 microg for topical delivery at the surgical site and 400 microg for distant sites.

Administration, Buccal↗
PubMed1999

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.

To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in the treatment of patients with severe, sight-threatening, intermediate and posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. Patients with uveitis were treated with a minimum of 20 mg of prednisone, cyclosporine, antimetabolites, or any combination of these agents were eligible. Patients were weaned off their systemic immunosuppressive agents according to a standardized schedule, while ultimately receiving Daclizumab infusions every 4 weeks. Anti-IL-2 receptor antibody therapy, given intravenously with intervals of up to 4 weeks in lieu of standard immunosuppressive therapy, appeared to prevent the expression of severe sight-threatening intraocular inflammatory disease in 8 of 10 patients treated over a 12-month period, with noted improvements in visual acuity. One patient met a primary endpoint with a loss of vision of 10 letters or more from baseline in one eye and another patient discontinued therapy because of evidence of increased ocular inflammation. All patients were able to tolerate the study medications without the need for dose reduction. We report effective long-term use of anti-IL-2 therapy for an autoimmune indication. These initial findings would suggest that anti-IL-2 receptor therapy may be an effective therapeutic approach for uveitis and, by implication, other disorders with a predominant Th1 profile.

Adult↗
PubMed1999

Disposition of alendronate following local delivery in a rat jaw.

BACKGROUND: Recently, we have shown that local delivery of alendronate reduced significantly bone resorption activated by surgical separation of periosteum from bone. These results advocate the use of local application of alendronate in bone surgeries to prevent regional bone resorption at the surgery site. Here we investigated the efficacy of absorbtion of alendronate by the bone from a gelatin sponge soaked with radiolabeled alendronate applied topically at the surgical site. METHODS: Following elevation of the mucoperiosteal flap next to premolars and molars of the rat mandible, a gelatin sponge soaked with 10 microl of radiolabled alendronate (1 microCi/mg) was applied to exposed bone on one side. The local absorbtion of alendronate and its disposition in the contralateral side of the mandible as well as in the tibia bone were analyzed. RESULTS: The results show that 10% of total alendronate content of the gelatin sponge was absorbed in the bone locally (in the surgical site), while 0.2% was disposed in the tibia. Of interest is the fact that the surgical wound in the contralateral side increased the disposition of alendronate up to 2%. This finding is most likely the result of extravasation and diffusion of alendronate due to surgical wounding. CONCLUSION: This study strongly supports our notion that local delivery of alendronate and its affinity to bone may become a very important treatment modality to prevent resorption of bone during dental and orthopedic procedures.

Absorption↗
PubMed1997

Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.

Mucoperiosteal flaps are used to access the bone and root surface in a wide range of periodontal procedures and in implant surgery. We have demonstrated that the mucoperiosteal surgical flap of the rat mandible produces a transient burst of alveolar bone resorption similar to the clinical observations in humans. This resorptive activity, when coupled with local irritation factors, may cause confined alveolar bone loss. Recently, we have demonstrated that an amino bisphosphonate, which is used in preventing systemic bone resorption in osteoporosis and other bone diseases, reduces alveolar bone resorption in the rat model when administered systemically. In this study we evaluated the effect of local delivery of the amino bisphosphonate on bone resorption associated with mucoperiosteal flaps. Following mucoperiosteal flap elevation in the premolar and molar region of the rat mandible, a surgical pellet soaked with amino bisphosphonate was locally applied on the exposed bone surface and covered by flap. The results show that local delivery of amino bisphosphonate reduces significantly alveolar bone resorption activated by mucoperiosteal flap surgery. This study suggests that local application of amino bisphosphonate can be used as an adjunct in therapy for reducing bone resorption following surgery.

Administration, Topical↗
PubMed1996

Skeletal and functional effects of treatment for unilateral posterior crossbite.

Unilateral posterior crossbite (UPXB) is a common malocclusion, frequently presenting a lower midline deviation, accompanied by Class II subdivision relationships in final closure and a very high prevalence of the reverse sequencing (RS) pattern of jaw movement. These features often persist even after the elimination of the crossbite. The purpose of the present study was to examine in detail the morphologic, skeletal, and functional effects of the treatment for this malocclusion category. The experimental group consisted of 24 children in the mixed dentition stage with UPXB who were treated with removable expansion plates and a control group of 10 age-matched children with normal occlusion. Longitudinal follow-up revealed a stable dental maxillary arch expansion of at least 1.5 mm but a complete elimination of crossbite in only 50% of the cases. The frequent persistence of Class II subdivision relations and lower midline deviation that were not due to functional mandibular shift was striking. The pretreatment posteroanterior (P-A) cephalograms indicated reduced facial and maxillary widths. After treatment, the achieved maxillary width increase was greater than expected with normal growth. Longitudinal assessment of the mandibular movement response revealed by the electrognathograph showed a high prevalence of RS, which was reduced after treatment. In conclusion, (1) a higher than expected prevalence of skeletal transverse aberrations at the maxillary and zygomatic levels were found in the UPXB group; (2) the removable expansion appliance induces transverse growth of the maxilla; and (3) an inherent pattern of jaw movement is characteristic to the UPXB and does not change significantly with orthodontic treatment.

Case-Control Studies↗
PubMed1996

Inhibition of 2-5A synthetase expression by antisense RNA interferes with interferon-mediated antiviral and antiproliferative effects and induces anchorage-independent cell growth.

It has been shown previously that the IFN-induced enzyme 2-5A synthetase is sufficient to induce antiviral and antiproliferative effects in transfected cells expressing the protein. In this study, the possibility that this enzyme is also essential in generating these biological activities was investigated. For this purpose, a plasmid, pMSas-NEO, was constructed. This plasmid carries an active neomycin-resistant gene. In addition, it contains a metallothionein promoter fused to an inverted 180-bp fragment derived from the 5' end of cDNA encoding the 43-kDa isoform of murine 2-5A synthetase. NIH/3T3 mouse fibroblasts were transfected with the plasmid, about 50 neomycin-resistant clones were isolated, and two, clone 11 and clone 22, were chosen for further studies. One clone transfected only with the neomycin-resistant gene, clone Neo, was used as a control. The results show that in the case of clone 11, the combined treatment of IFN and ZnCl2 reduced significantly the level of the IFN-induced 2-5A synthetase activity, the amount of the 40-, 43-, and 71-kDa 2-5A synthetase isoforms and the level of the 1.7-kb specific RNA transcript. An even stronger effect on these parameters was observed with clone 22 cells. No difference in PKR activity was evident under the same conditions with all three clones tested. Most important, the combined treatment of IFN and ZnCl2 reversed the IFN-mediated antiproliferative and antiviral activities, as determined by the kinetics of cell growth, thymidine incorporation, cloning efficiency, and infection with mengovirus. Strikingly, the growth of colonies in soft agar were observed in both clone 11 (small colonies) and clone 22 (large colonies) cells, particularly following treatment with ZnCl2. We conclude that 2-5A synthetase is an essential component in the IFN-induced biological activities and that interference with its function results in anchorage-independent growth of the transfected cells.

2',5'-Oligoadenylate Synthetase↗
PubMed1996

Physiologic occlusion vs pathologic occlusion and rationale for treatment.

Treatment concepts in dentistry are generally based on a preconceived normal state derived from clinical observation and theories rather than scientific evidence. Before treatment is proposed, the clinician should observe physiologic signs and symptoms to determine the presence of a particular pathology. This article presents different theories of occlusion, diagnostic characteristics that can be used to distinguish between physiologic occlusion and pathologic occlusion requiring treatment, and guidelines for reconstructive occlusal therapy.

Adult↗
PubMed1995

Tooth contact during dynamic lateral excursion in young adults.

Tooth contact in mediotrusion as well as the signs and symptoms of periodontal and mandibular dysfunction were recorded in healthy patients aged between 20 and 31 with Angle class I or II. Non-functional side contact (NFSC) was found in 94% of the patients, indicating that it is a common phenomenon. In cases of NFSC, the entire range of movement, and not only the final stage of tip-to-tip contact on the working side, should be recorded. Slight positive mobility with tooth faceting, as compared to the adjacent and contralateral teeth, was observed in 56 patients. There was no correlation between mediotrusion and mandibular dysfunction. The cumulative effects of NFSC are not well documented, and longitudinal follow-up studies should be carried out to clarify these.

Adult↗
PubMed1995

The effect of bisphosphonate on alveolar bone resorption following mucoperiosteal flap surgery in the mandible of rats.

Following elevation of a full thickness flap a transient burst of regional remodeling occurs. This phenomenon is termed in orthopedic surgery as regional accelerated phenomenon (RAP), beginning with accelerated resorption activity followed by a slow process of bone regeneration. Recently we have demonstrated that a mucoperiosteal surgical flap of rat mandible is producing a typical RAP process. Bisphosphonates are synthetic compounds that are taken up preferentially by the skeleton and suppress osteoclast-mediated bone resorption by a mechanism that is not yet fully understood. Amino bisphosphonate has been shown to inhibit active bone resorption without interfering with bone formation. In this study we evaluated the effect of amino bisphosphonate on bone resorption associated with a mucoperiosteal flap used as a resorptive model. We compared the effect of amino bisphosphonate in rats using IV administration with topical application at 3 dose levels. The results show that topical application of all 3 doses (0.15, 0.75, and 1.5 mg/ml) had no inhibiting effect on bone resorption after surgery, while IV administration at 0.5 mg/kg body weight significantly reduced the bone resorption. Interestingly, in the non-operated side, amino bisphosphonate increased mineral density.

Administration, Topical↗